Literature DB >> 35934680

Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease.

Archana Shankar1, Jaclyn W McAlees2, Ian P Lewkowich3.   

Abstract

Aberrant activation of CD4 TH2 cells and excessive production of TH2 cytokines such as IL-4 and IL-13 have been implicated in the pathogenesis of allergic diseases. Generally, IL-4 and IL-13 utilize Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathways for induction of inflammatory gene expression and the effector functions associated with disease pathology in many allergic diseases. However, it is increasingly clear that JAK/STAT pathways activated by IL-4/IL-13 can themselves be modulated in the presence of other intracellular signaling programs, thereby changing the overall tone and/or magnitude of IL-4/IL-13 signaling. Apart from direct activation of the canonic JAK/STAT pathways, IL-4 and IL-13 also induce proinflammatory gene expression and effector functions through activation of additional signaling cascades. These alternative signaling cascades contribute to several specific aspects of IL-4/IL-13-associated cellular and molecular responses. A more complete understanding of IL-4/IL-13 signaling pathways, including the precise conditions under which noncanonic signaling pathways are activated, and the impact of these pathways on cellular- and host-level responses, will better allow us to design agents that target specific pathologic outcomes or tailor therapies for the treatment of uncommon disease endotypes.
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergic disease; IL-13; IL-4; cytokine signaling

Mesh:

Substances:

Year:  2022        PMID: 35934680      PMCID: PMC9371363          DOI: 10.1016/j.jaci.2022.06.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   14.290


  163 in total

1.  SHP-1 regulates STAT6 phosphorylation and IL-4-mediated function in a cell type-specific manner.

Authors:  Zan Huang; John M Coleman; Yan Su; Meredith Mann; John Ryan; Leonard D Shultz; Hua Huang
Journal:  Cytokine       Date:  2004-12-01       Impact factor: 3.861

Review 2.  Tyrosine phosphatase SHP-1 in allergic and anaphylactic inflammation.

Authors:  Zhou Zhu; Sun Young Oh; You Sook Cho; Li Zhang; Yoon-Keun Kim; Tao Zheng
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 3.  Regulation of IL-4 Expression in Immunity and Diseases.

Authors:  I-Cheng Ho; Shi-Chuen Miaw
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  SHP-1 as a critical regulator of Mycoplasma pneumoniae-induced inflammation in human asthmatic airway epithelial cells.

Authors:  Ying Wang; Zhou Zhu; Tony D Church; Njira L Lugogo; Loretta G Que; Dave Francisco; Jennifer L Ingram; Molly Huggins; Denise M Beaver; Jo Rae Wright; Monica Kraft
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

5.  A role for the insulin-interleukin (IL)-4 receptor motif of the IL-4 receptor alpha-chain in regulating activation of the insulin receptor substrate 2 and signal transducer and activator of transcription 6 pathways. Analysis by mutagenesis.

Authors:  H Y Wang; J Zamorano; A D Keegan
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

6.  The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.

Authors:  R A Seder; W E Paul; M M Davis; B Fazekas de St Groth
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

Review 7.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

8.  PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production.

Authors:  I P Lewkowich; S Lajoie; S L Stoffers; Y Suzuki; P K Richgels; K Dienger; A A Sproles; H Yagita; Q Hamid; M Wills-Karp
Journal:  Mucosal Immunol       Date:  2012-11-14       Impact factor: 7.313

9.  Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity.

Authors:  Jung-Eun Kim; Keunok Jung; Jeong-Ah Kim; Seung-Hyun Kim; Hae-Sim Park; Yong-Sung Kim
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

10.  Loss of protein tyrosine phosphatase non-receptor type 2 reduces IL-4-driven alternative macrophage activation.

Authors:  Marianne R Spalinger; Meli'sa Crawford; Sarah D Bobardt; Jiang Li; Anica Sayoc-Becerra; Alina N Santos; Ali Shawki; Pritha Chatterjee; Meera G Nair; Declan F McCole
Journal:  Mucosal Immunol       Date:  2021-08-21       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.